文献速递膀胱癌与上尿路尿路上皮癌

治疗中改良格拉斯哥预后评分可为接受免疫治疗的转移性尿路上皮癌提供放射学分期之外的预测信息

On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.
PubMed 文献 · Eur Urol Oncol · 2023-11-22

在免疫治疗时代,仅凭放射学分期难以预测转移性尿路上皮癌患者的预后,尤其对疾病稳定(SD)亚组。本研究基于2期IMvigor210和3期IMvigor211试验,评估治疗中改良格拉斯哥预后评分(mGPS)的预后价值,发现其可提供放射学分期之外的补充预测信息,尤其在SD患者中,且在IMvigor210中最早于免疫检查点抑制剂(ICI)启动后6周即可预测结局。

要点

  • 治疗中mGPS可提供放射学分期之外的补充预后信息,尤其对疾病稳定患者。
  • 在IMvigor210中,治疗中mGPS最早于ICI启动后6周即可预测结局。
  • mGPS仅基于血清C反应蛋白和白蛋白,可能成本效益较好。

核心结论

  • 治疗中mGPS可补充放射学影像预测接受ICI的转移性尿路上皮癌患者的结局。

研究设计与样本

  • 基于2期IMvigor210和3期IMvigor211试验,评估治疗中mGPS在接受ICI治疗的转移性尿路上皮癌患者中的预后价值。

主要发现

  • 治疗中mGPS提供有价值的预后信息,补充放射学分期,尤其对疾病稳定(SD)患者。
  • 在IMvigor210中,治疗中mGPS最早于ICI启动后6周即可预测结局,明显早于通常在10-12周后进行的首次常规分期。

临床怎么用

  • 作者认为,治疗中mGPS可补充放射学影像,用于预测接受ICI的转移性尿路上皮癌患者的结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the immunotherapy era it is difficult to predict patient prognosis on the basis of radiological staging alone, especially for the subgroup with stable disease (SD), which encompasses a wide range of clinical outcomes. Thus, there is need for reliable and, ideally, cost-efficient biomarkers to improve the accuracy of outcome prediction. We evaluated the on-treatment modified Glasgow Prognostic Score (mGPS)-a known predictor of outcomes in several cancers that is based on serum C-reactive protein and albumin-in patients with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibition (ICI) in the phase 2 IMvigor210 and phase 3 IMvigor211 trials. On-treatment mGPS provides valuable prognostic information complementary to radiological staging, particularly for patients with SD. In IMvigor210, on-treatment mGPS predicts outcomes as early as 6 wk after ICI initiation, considerably before the first routine staging typically performed after 10-12 wk. Our study suggests that on-treatment mGPS complements radiological imaging in predicting outcomes for patients with mUC undergoing ICI. PATIENT SUMMARY: For patients with metastatic bladder cancer receiving immunotherapy, it is difficult to predict treatment outcomes from imaging scans alone. Our study results suggest that a score called the modified Glasgow Prognostic Score based on just two proteins (C-reactive protein and albumin) measured in blood can accurately predict outcomes. Use of the mGPS along with imaging scans may be better in predicting the survival benefit from immunotherapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Saal J, Grünwald V, Bald T, et al. On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. Eur Urol Oncol. 2023. PMID: 37996277. doi:10.1016/j.euo.2023.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。